Perrigo Co. (Nasdaq: PRGO) has completed its acquisition of Cobrek Pharmaceuticals Inc., a Chicago drug-development company, for $45 million in cash.

The buyer already held an 18.5 percent stake in Cobrek, which it purchased in May 2008.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.